Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 0.2% – Time to Sell?

Xilio Therapeutics, Inc. (NASDAQ:XLO) dropped 0.2% during trading on Thursday . The company traded as low as $8.82 and last traded at $9.08. 4,960 shares traded hands during trading, a decline of 90% from the average session volume of 49,059 shares. The stock had previously closed at $9.10.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Wall Street Zen cut Xilio Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings raised Xilio Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.00.

Xilio Therapeutics Stock Up 0.3%

The firm’s 50-day simple moving average is $8.73 and its 200 day simple moving average is $8.37. The stock has a market capitalization of $59.94 million, a P/E ratio of -2.57 and a beta of -0.14.

Xilio Therapeutics (NASDAQ:XLO) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.08. The company had revenue of $12.65 million during the quarter, compared to the consensus estimate of $8.52 million. Xilio Therapeutics had a negative net margin of 58.52% and a negative return on equity of 151.42%.

Institutional Trading of Xilio Therapeutics

A number of large investors have recently added to or reduced their stakes in XLO. Jane Street Group LLC bought a new position in shares of Xilio Therapeutics in the fourth quarter valued at $27,000. Velan Capital Investment Management LP bought a new stake in shares of Xilio Therapeutics during the 4th quarter worth $109,000. State Street Corp boosted its stake in shares of Xilio Therapeutics by 13.7% during the 4th quarter. State Street Corp now owns 186,390 shares of the company’s stock worth $119,000 after acquiring an additional 22,500 shares in the last quarter. Squarepoint Ops LLC grew its holdings in shares of Xilio Therapeutics by 39.6% in the 3rd quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after acquiring an additional 93,338 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Xilio Therapeutics by 68.3% in the 4th quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock worth $220,000 after acquiring an additional 139,716 shares during the last quarter. 54.29% of the stock is currently owned by institutional investors.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.